The prevalence and incidence of cardiovascular conditions in developed economies continue to increase, creating challenges and opportunities for cardiovascular drug developers. While the vast majority of drugs for treating cardiovascular conditions are oral immediate release products, issues related to drug safety and patient compliance have focused attention on formulations that can improve drug safety profiles and reduce dosing frequency. Important treatment segments for controlled release cardiovascular drugs include angina, hypertension, arrhythmias, cholesterol, and peripheral artery disease. Important growth factors for controlled release cardiovascular drugs include evolving patient demographics, environmental and lifestyle causative factors, increased public awareness of cardiovascular conditions and their associated morbidities, and expanded patient access to cardiovascular treatment services.
Controlled Release Cardiovascular Therapeutics - What You Will Learn
- Analyzes and evaluates controlled release cardiovascular drug products and assesses the market potential for existing and probable future products
- Analyzes product strategies, technologies and market development issues
- Provides detailed analysis of cardiovascular market segments, market demographics, and therapeutic strategies
- Profiles market sector companies, their product development activities, business strategies, and corporate alliances and affiliations
- Evaluates the impact of economic, technology, and regulatory factors on cardiovascular drug markets
Table of Contents
- Executive Summary
- Cardiovascular Therapeutics - Market Dynamics
- The Cardiovascular Drug Landscape
- Unmet Needs in Cardiovascular Clinical Treatment
- Cardiovascular Drug Demand Drivers
- Demographic Shifts
- Evolving Drug Formulation Technology
- Managed Care Initiatives
- Growth in Self Administration
- Modified Release Technologies
- Oral
- Advanced Film Coating Systems
- Bead Systems
- Bi-layer Tablets
- Tri-layer Tablets
- Microtablets
- Transdermal
- Cardiovascular Controlled Release Product Analysis
- Cardiovascular Drug Commercialization Factors
- Cardiovascular Segments for CR Therapeutics
- Angina
- Cholesterol Management
- Heart Rhythm
- Hypertension
- Peripheral Artery Disease
- Market Factors
- Regulations and Approvals
- US (FDA)
- EU (EMEA)
- Japan (PMDA)
- Australia (TGA)
- Managed Care and Healthcare Economics
- Sector Participant Company Profiles
Samples
LOADING...
